.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,942,498

« Back to Dashboard

Details for Patent: 5,942,498

Title: Formulations containing hyaluronic acid
Abstract:Topically applied transdermally quick penetrating compositions containing a drug and hyaluronic acid and/or salts thereof and methods of treating diseases and conditions employing said compositions.
Inventor(s): Falk; Rudolf Edger (Toronto, CA), Asculai; Samuel Simon (Toronto, CA), Klein; Ehud Shmuel (Givat Savyon, IL), Harper; David William (Oakville, CA), Hochman; David (Thornhill, CA), Purschke; Don (Toronto, CA)
Assignee: Hyal Pharmaceutical Corporation (Mississauga, CA)
Filing Date:Jun 06, 1995
Application Number:08/467,171
Claims:1. A pharmaceutical composition from which an effective non-toxic dosage amounts are to be taken and applied topically to the skin or exposed tissue of a human, each effective dosage amount consisting essentially of pharmaceutical excipients suitable for topical application, an effective non-toxic dosage amount of a drug to treat diseases and conditions of the skin or exposed tissue of a human and an effective non-toxic dosage amount of a form of hyaluronic acid selected from the group consisting of hyaluronic acid, non-toxic salts thereof and combination thereof having a molecular weight less than 750,000 daltons and greater than 150,000 daltons sufficient to transport the drug percutaneously into the epidermis of the skin or exposed tissue of a site in need of treatment wherein the composition accumulates and remains in the epidermis for a prolonged period of time and which is systemic independent acting and wherein the drug in the pharmaceutical composition is between about 1% and about 5% by weight of the composition and the amount of the form of hyaluronic acid in the composition is between about 1% and about 3% by weight of the composition and wherein each dosage to be taken comprises a minimum of 5 mg of the form of hyaluronic acid per square centimeter of skin or exposed tissue to which it is to be applied.

2. The composition of claim 1 wherein the drug is a non-steroidal anti-inflammatory agent (NSAID) in an amount between about 1% and about 5% of the composition by weight and the pharmaceutical excipients include a preservative and a solubilizer for the NSAID.

3. The composition of claim 2 wherein the form of the composition is selected from the group consisting of a gel and cream suitable for topical application and wherein the NSAID is 3% by weight diclofenac, the form of hyaluronic acid is present as 21/2% by weight of the composition, and the pharmaceutical excipients include a solubilizer for solubilizing the diclofenac, and a preservative.

4. The composition of claim 3 wherein the preservative is benzyl alcohol present as 1% by weight of the composition and the solubilizer is methoxypolyethylene glycol present as 20% by weight of the composition.

5. The composition of claim 3 suitable for topical application wherein the pharmaceutical excipients include 20% by weight methoxypolyethylene glycol, 1% by weight benzyl alcohol, 3% by weight diclofenac sodium, 2.5% by weight sodium hyaluronate, and the balance is sterile water.

6. The composition of claim 2 wherein the form of said composition is in a form for topical application, further including

between about 1 to about 3% by weight of the composition of sodium hyaluronate having a molecular weight less than about 750,000 daltons and greater than about 150,000 daltons

between about 1 to about 5% by weight of the composition of an NSAID and the balance selected from the group consisting of excipients suitable for topical application and water.

7. A dosage amount of a pharmaceutical composition consisting essentially of

(1) pharmaceutical excipients suitable for topical application including water;

(2) a therapeutic agent in a therapeutically effective amount to treat a disease or condition of the skin and exposed tissue and;

(3) a form of hyaluronic acid selected from the group consisting of hyaluronic acid and non-toxic salts thereof, having a molecular weight less than 750,000 daltons and greater than 150,000 daltons,

characterized in that said dosage amount of said composition is in a dosage form suitable for topical application to the skin and exposed tissue, is in a dosage amount in which component (2) exceeds 5 mg/cm.sup.2 of the skin or exposed tissue to which the dosage amount is to be applied, and is in such form that component (3) is immediately available to transport component (2) percutaneously into the epidermis of the skin or exposed tissue to the site of trauma and pathology of the disease or condition to be treated in the skin or exposed tissue, where the dosage amount of the composition accumulates (in the epidermis) for a prolonged period before passage therefrom, and wherein the concentrations by weight of components (2) and (3) in the dosage amount are selected from:

(i) component (3) equals or is less than 3% by weight of the dosage amount but equal to or greater than 1% by weight of the dosage amount and component (2) equals or is less than 5% by weight of the dosage amount but equal to or greater than 1% by weight of the dosage amount, and

(ii) component (3) is about 21/2% by weight of the dosage amount and component (2) is 3% by weight of the dosage amount.

8. The dosage amount of claim 7 wherein the concentration of components (2) and (3) in the dosage amounts is that in subparagraph (i).

9. The dosage amount of claim 7 wherein the concentration of components (2) and (3) in the dosage amounts is that in subparagraph (ii).

10. The dosage amount of claim 8 wherein component (2) is an NSAID.

11. The dosage amount of claim 9 wherein component (2) is an NSAID.

12. The dosage amount of claim 10 wherein component (3) exceeds 10 mg/cm.sup.2.

13. The dosage amount of claim 11 wherein component (3) exceeds 10 mg/cm.sup.2.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc